{"id":54651,"date":"2023-03-08T22:03:09","date_gmt":"2023-03-08T21:03:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/"},"modified":"2023-03-08T22:03:09","modified_gmt":"2023-03-08T21:03:09","slug":"nanostring-reports-inducement-grants-under-nasdaq-listing-rules","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/","title":{"rendered":"NanoString Reports Inducement Grants Under Nasdaq Listing Rules"},"content":{"rendered":"
\n

SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 16 new employees.\n<\/p>\n

<\/a><\/p>\n

\nIn accordance with Nasdaq Listing Rule 5635(c)(4), on March 4, 2023, the Compensation and Human Capital Committee of NanoString\u2019s Board of Directors approved the grant of, in the aggregate, 144,767 restricted stock units, or RSUs, as material inducements to the 16 employees entering into employment with NanoString. One-third of the RSUs vest on the first market trading day on or following the first anniversary of the grant date and one-third of the RSUs vest annually each year on the first market trading day on or after the second and third anniversaries of the grant date, subject to each employee\u2019s continued service through each such date.\n<\/p>\n

\nThe inducement RSU awards were made outside of NanoString\u2019s current equity plan, the 2022 Equity Incentive Plan, and under NanoString’s 2018 Inducement Equity Incentive Plan and related award agreements, but will be subject to terms and conditions generally consistent with those in the 2022 Equity Incentive Plan.\n<\/p>\n

\nAbout NanoString<\/b>\n<\/p>\n

\nNanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx\u00ae Digital Spatial Profiler, cited in approximately 200 peer-reviewed publications, is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics from one FFPE slide. The CosMx\u2122 Spatial Molecular Imager is an FFPE-compatible, single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx\u2122 Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter\u00ae Analysis System, cited in approximately 6,500 peer-reviewed publications, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.\n<\/p>\n

\nFor more information, please visit www.nanostring.com<\/a>.\n<\/p>\n

\nNanoString, NanoString Technologies, the NanoString logo, GeoMx, CosMx, AtoMx and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nDoug Farrell
\n
Vice President, Investor Relations & Corporate Communications
\n
dfarrell@nanostring.com<\/a>
Phone: 206-602-1768\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 16 new employees. In accordance with Nasdaq Listing Rule 5635(c)(4), on March 4, 2023, the Compensation and Human Capital Committee of NanoString\u2019s Board of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54651","6":"format-standard","7":"category-industry"},"yoast_head":"\nNanoString Reports Inducement Grants Under Nasdaq Listing Rules - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NanoString Reports Inducement Grants Under Nasdaq Listing Rules - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 16 new employees. In accordance with Nasdaq Listing Rule 5635(c)(4), on March 4, 2023, the Compensation and Human Capital Committee of NanoString\u2019s Board of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-08T21:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230308005353\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NanoString Reports Inducement Grants Under Nasdaq Listing Rules\",\"datePublished\":\"2023-03-08T21:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/\"},\"wordCount\":409,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005353\\\/en\\\/1070856\\\/21\\\/4891105_NSTG_logo_for_Yahoo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/\",\"name\":\"NanoString Reports Inducement Grants Under Nasdaq Listing Rules - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005353\\\/en\\\/1070856\\\/21\\\/4891105_NSTG_logo_for_Yahoo.jpg\",\"datePublished\":\"2023-03-08T21:03:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005353\\\/en\\\/1070856\\\/21\\\/4891105_NSTG_logo_for_Yahoo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005353\\\/en\\\/1070856\\\/21\\\/4891105_NSTG_logo_for_Yahoo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NanoString Reports Inducement Grants Under Nasdaq Listing Rules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NanoString Reports Inducement Grants Under Nasdaq Listing Rules - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/","og_locale":"en_US","og_type":"article","og_title":"NanoString Reports Inducement Grants Under Nasdaq Listing Rules - Pharma Trend","og_description":"SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 16 new employees. In accordance with Nasdaq Listing Rule 5635(c)(4), on March 4, 2023, the Compensation and Human Capital Committee of NanoString\u2019s Board of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-08T21:03:09+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230308005353\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NanoString Reports Inducement Grants Under Nasdaq Listing Rules","datePublished":"2023-03-08T21:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/"},"wordCount":409,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230308005353\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/","url":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/","name":"NanoString Reports Inducement Grants Under Nasdaq Listing Rules - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230308005353\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg","datePublished":"2023-03-08T21:03:09+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230308005353\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230308005353\/en\/1070856\/21\/4891105_NSTG_logo_for_Yahoo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nanostring-reports-inducement-grants-under-nasdaq-listing-rules\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NanoString Reports Inducement Grants Under Nasdaq Listing Rules"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54651"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54651\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}